JPWO2023016348A5 - - Google Patents
Info
- Publication number
- JPWO2023016348A5 JPWO2023016348A5 JP2024508097A JP2024508097A JPWO2023016348A5 JP WO2023016348 A5 JPWO2023016348 A5 JP WO2023016348A5 JP 2024508097 A JP2024508097 A JP 2024508097A JP 2024508097 A JP2024508097 A JP 2024508097A JP WO2023016348 A5 JPWO2023016348 A5 JP WO2023016348A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- set forth
- hcdr2
- hcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110909032.3 | 2021-08-09 | ||
| CN202110909032 | 2021-08-09 | ||
| PCT/CN2022/110314 WO2023016348A1 (en) | 2021-08-09 | 2022-08-04 | Cldn18.2-targeting antibody, bispecific antibody and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024531944A JP2024531944A (ja) | 2024-09-03 |
| JP2024531944A5 JP2024531944A5 (https=) | 2025-08-04 |
| JPWO2023016348A5 true JPWO2023016348A5 (https=) | 2025-08-04 |
Family
ID=82942472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508097A Pending JP2024531944A (ja) | 2021-08-09 | 2022-08-04 | Ｃｌｄｎ１８．２標的化抗体、二重特異性抗体、及びそれらの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12428479B2 (https=) |
| EP (1) | EP4384547A1 (https=) |
| JP (1) | JP2024531944A (https=) |
| KR (1) | KR20240044467A (https=) |
| CN (1) | CN118019763A (https=) |
| AR (1) | AR126739A1 (https=) |
| AU (1) | AU2022326063A1 (https=) |
| CA (1) | CA3228137A1 (https=) |
| CL (1) | CL2024000374A1 (https=) |
| CO (1) | CO2024002857A2 (https=) |
| CR (1) | CR20240124A (https=) |
| EC (1) | ECSP24018785A (https=) |
| IL (1) | IL310578A (https=) |
| MX (1) | MX2024001761A (https=) |
| TW (1) | TW202334215A (https=) |
| WO (1) | WO2023016348A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115667316A (zh) * | 2020-06-30 | 2023-01-31 | 和铂医药(上海)有限责任公司 | Fab-HCAb结构的结合蛋白 |
| CN119569886A (zh) * | 2023-09-06 | 2025-03-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| CN120829517A (zh) * | 2024-04-22 | 2025-10-24 | 鲁南新时代生物技术有限公司 | 抗cldn18.2/cd3双特异性抗体及用途 |
| WO2026076388A1 (en) * | 2024-10-03 | 2026-04-09 | The Broad Institute, Inc. | Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| WO2014075788A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016180468A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| EP3356410B1 (en) | 2015-10-02 | 2021-10-20 | F. Hoffmann-La Roche AG | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| JP6763529B2 (ja) | 2016-12-28 | 2020-09-30 | 国立医薬品食品衛生研究所長 | 抗クローディン−２モノクローナル抗体 |
| RU2020124623A (ru) * | 2017-12-27 | 2022-01-27 | Тенеобио, Инк. | Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон |
| CN112770723B (zh) | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| JOP20210022A1 (ar) | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| US20220184126A1 (en) | 2019-03-29 | 2022-06-16 | Phanes Therapeutis, Inc. | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
| WO2020238730A1 (zh) * | 2019-05-24 | 2020-12-03 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| EP3999091A1 (en) * | 2019-07-15 | 2022-05-25 | MedImmune Limited | Tripartite systems for protein dimerization and methods of use |
| JP2022541435A (ja) * | 2019-07-17 | 2022-09-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン１８抗体及びがんを処置する方法 |
| KR102936430B1 (ko) * | 2019-12-27 | 2026-03-11 | 레전드 바이오테크 아일랜드 리미티드 | Claudin18.2 결합 모이어티 및 이의 용도 |
| TWI838621B (zh) * | 2020-04-29 | 2024-04-11 | 美商泰尼歐萬公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| US20240109963A1 (en) * | 2020-11-16 | 2024-04-04 | Ab Therapeutics, Inc. | Multispecific antibodies and uses thereof |
| CN112480248B (zh) * | 2020-11-24 | 2023-05-05 | 三优生物医药(上海)有限公司 | 与cld18a2特异性结合的分子 |
-
2022
- 2022-08-04 CR CR20240124A patent/CR20240124A/es unknown
- 2022-08-04 CA CA3228137A patent/CA3228137A1/en active Pending
- 2022-08-04 AU AU2022326063A patent/AU2022326063A1/en active Pending
- 2022-08-04 EP EP22757202.1A patent/EP4384547A1/en active Pending
- 2022-08-04 CN CN202280054294.9A patent/CN118019763A/zh active Pending
- 2022-08-04 WO PCT/CN2022/110314 patent/WO2023016348A1/en not_active Ceased
- 2022-08-04 KR KR1020247007499A patent/KR20240044467A/ko active Pending
- 2022-08-04 JP JP2024508097A patent/JP2024531944A/ja active Pending
- 2022-08-04 MX MX2024001761A patent/MX2024001761A/es unknown
- 2022-08-04 IL IL310578A patent/IL310578A/en unknown
- 2022-08-08 TW TW111129765A patent/TW202334215A/zh unknown
- 2022-08-08 AR ARP220102131A patent/AR126739A1/es unknown
- 2022-08-08 US US17/818,072 patent/US12428479B2/en active Active
-
2024
- 2024-02-07 CL CL2024000374A patent/CL2024000374A1/es unknown
- 2024-03-07 EC ECSENADI202418785A patent/ECSP24018785A/es unknown
- 2024-03-08 CO CONC2024/0002857A patent/CO2024002857A2/es unknown
-
2025
- 2025-07-18 US US19/273,244 patent/US20250340631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7547581B2 (ja) | 腫瘍治療薬及びその応用 | |
| KR102340832B1 (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP2019511212A (ja) | ヒトポリオウイルス受容体（ｐｖｒ）に特異的な抗体 | |
| AU2020207664B2 (en) | Antibodies specific to human Nectin-2 | |
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| WO2002085946A1 (en) | Bispecific antibodies that bind trail-r1 and trail-r2 | |
| US20160039938A1 (en) | Antibodies against human and canine il-13ra2 | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| WO2021244554A1 (zh) | 抗pdl1×egfr的双特异性抗体 | |
| US8691229B2 (en) | Method of PLSCR inhibition for cancer therapy | |
| JPWO2023016348A5 (https=) | ||
| JP2024541175A (ja) | Ｈｅｒｖ－ｋ抗体治療法 | |
| WO2023065594A1 (zh) | 抗cd47-cldn18.2双特异性抗体及其用途 | |
| CN114805581A (zh) | 靶向il13ra2的抗体、嵌合抗原受体及其用途 | |
| JP7451506B2 (ja) | がんの治療用の薬学的組合せ | |
| CN101233155B (zh) | 人抗表皮生长因子受体抗体 | |
| KR20240072932A (ko) | B7-h3에 특이적으로 결합하는 항체 | |
| CN117624352A (zh) | 抗Tmem176b抗体、药物组合物及用途 | |
| JP7357347B2 (ja) | 細胞外のＰＫＣδを標的とする肝癌細胞増殖抑制剤及びそれを含む新規肝癌治療薬 | |
| WO2022121846A1 (zh) | Pd-l1抗体及其应用 | |
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| US20260116971A1 (en) | Antibodies specific to human nectin-2 | |
| TW202530217A (zh) | 靶向細胞粘附蛋白（ｎｅｃｔｉｎ）４且包含依沙替康（ｅｘａｔｅｃａｎ）藥載之抗體藥物結合物（ａｄｃ） | |
| KR20240082201A (ko) | B7-h3 키메라 항원 수용체 및 이의 용도 | |
| HK40097873A (zh) | 用於治疗癌症的组合疗法 |